早期肺超声评分变化预测急性低氧患者无创呼吸支持失败:一项多中心前瞻性观察研究
该多中心前瞻性国际观察研究纳入100例因低氧血症(PaO2/FiO2<300 mmHg)接受无创呼吸支持(HFNC 13例、CPAP 68例、NIV 19例)的患者,在基线及治疗开始后2小时评估肺超声(LUS)评分、PaO2/FiO2和ROX指数。总体治疗失败率为22%。失败组2小时PaO2/FiO2更低(149 mmHg vs 200 mmHg,p=0.001)、ROX指数更低(7.8 vs 10.9,p=0.003)、侧区及全局LUS通气评分更高,且初始2小时内肺通气无改善(全局LUS评分变化0.0 vs -3.0,p<0.001)。ROX指数及前侧/全局LUS评分变化为失败的独立预测因子,联合临床-超声评分(ROX-US)AUC为0.82。
要点
- 无创呼吸支持2小时后LUS全局评分无改善(变化0.0 vs -3.0,p<0.001)提示治疗失败风险高。
- 失败组2小时PaO2/FiO2为149 mmHg vs 非失败组200 mmHg(p=0.001),ROX指数7.8 vs 10.9(p=0.003)。
- ROX-US评分≥2识别治疗成功的特异性96%、敏感性45%;ROX-US≥1敏感性95%、特异性50%。
- 2小时ROX指数、PaO2/FiO2及全局LUS评分变化的AUC分别为0.71、0.73、0.73,联合ROX-US评分AUC为0.82。
- 基线临床和超声参数在失败组与非失败组间相似,早期(2小时)动态变化比基线值更有预测价值。
适用人群与场景
- 因低氧血症(PaO2/FiO2 < 300 mmHg)接受无创呼吸支持(HFNC、CPAP或NIV)的患者。
- 本研究纳入100例患者,年龄70(57-76)岁,女性39%;支持方式:HFNC 13例、CPAP 68例、NIV 19例。
诊断标准与关键阈值
- 低氧血症定义:PaO2/FiO2 < 300 mmHg。
- 治疗失败定义:48小时内需要呼吸支持升级(HFNC升级至CPAP再至NIV,任何支持升级至插管/ECMO)。
- LUS通气评分:每侧胸壁6个区域(前2、侧2、后2),按4级通气丧失评分(0=正常,3=严重通气丧失),计算区域/全局评分。
- ROX-US≥1识别治疗成功:敏感性95%,特异性50%;ROX-US≥2识别治疗成功:敏感性45%,特异性96%。
研究设计与关键结果
- 多中心前瞻性国际观察研究,纳入100例接受无创呼吸支持的低氧血症患者,总体治疗失败率22%。
- 基线时失败组与非失败组临床和超声参数相似;2小时后失败组PaO2/FiO2更低(149 mmHg [124-201] vs 200 [171-243],p=0.001)、ROX指数更低(7.8 [4.9-9.2] vs 10.9 [7.9-13.8],p=0.003)。
- 2小时后失败组侧区LUS评分更高(3.0 [1.0-6.0] vs 1.5 [0.0-3.0],p=0.047)、前侧区更高(4.0 [1.0-9.0] vs 2.0 [0.0-4.0],p=0.027)、全局更高(13.0 [8.0-17.0] vs 10.0 [7.0-13.0],p=0.036)。
- 失败组初始2小时内肺通气无改善(全局LUS评分变化0.0 [-2.0-1.0] vs -3.0 [-5.0 - -2.0],p<0.001)。
- ROX指数及前侧/全局LUS评分变化为失败的独立预测因子;2小时ROX指数AUC 0.71 [0.58-0.84],2小时PaO2/FiO2 AUC 0.73 [0.60-0.85],全局LUS评分变化AUC 0.73 [0.62-0.89],联合ROX-US评分AUC 0.82 [0.73-0.91]。
证据类型、等级与局限
- 证据类型:多中心前瞻性国际观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,无创呼吸支持2小时诱导的LUS通气评分变化有助于早期预测治疗失败风险。
- LUS评分仅在治疗有反应者中改善,且为失败的独立预测因子。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: To determine whether lung ultrasound (LUS) may early predict the failure of non-invasive respiratory support (high-flow nasal cannula-HFNC, continuous positive airway pressure-CPAP, non-invasive ventilation-NIV) in hypoxemic patients.
METHODS: In this prospective multicenter international observational study, we enrolled patients undergoing non-invasive treatments for hypoxemia (PaO2/FiO2 < 300 mmHg). LUS, PaO2/FiO2 and ROX index were assessed before (baseline) and 2 h after treatment start. Regional/global LUS aeration scores were computed (4 degrees of loss-of-aeration: 0-normal to 3-severe loss of aeration) in 6 regions per hemithorax (2 anterior, 2 lateral, 2 posterior). Failure was defined as need of respiratory support's escalation within 48 h (HFNC to CPAP to NIV, any support to intubation/ECMO).
RESULTS: We studied 100 patients (age 70 [57-76] years; female sex 39%; supports: 13 HFNC, 68 CPAP, 19 NIV); the overall rate of treatment failure was 22%. At the baseline, clinical and ultrasound parameters were similar in failing and non-failing patients; after 2 h, failing patients had lower PaO2/FiO2. (149 mmHg [124-201] vs. 200 [171-243]; p = 0.001), lower ROX index (7.8 [4.9-9.2] vs. 10.9 [7.9-13.8]; p = 0.003) and higher lateral (3.0 [1.0-6.0] vs. 1.5 [0.0-3.0]; p = 0.047), antero-lateral (4.0 [1.0-9.0] vs. 2.0 [0.0-4.0]; p = 0.027) and global (13.0 [8.0-17.0] vs. 10.0 [7.0-13.0]; p = 0.036) LUS aeration scores. No improvement in lung aeration was observed in failing patients within the initial 2 h of treatment (global LUS score variations 0.0 [-2.0-1.0] vs. -3.0 [-5.0 - -2.0]; p < 0.001). ROX index and antero-lateral/global LUS scores' variations were independent predictors of failure. AUCs for treatment failure were: 2-hour ROX index 0.71 [0.58-0.84], 2-hour PaO2/FiO2 0.73 [0.60-0.85], global LUS score variations 0.73 [0.62-0.89]. A combined clinical-ultrasound score (ROX-US) showed AUC of 0.82 [0.73-0.91]. A ROX-US≥1 identified the success of the treatment with sensitivity 95% and specificity 50%; a ROX-US≥2 identified the success of the treatment with sensitivity 45% and specificity 96%.
CONCLUSIONS: Changes in LUS aeration scores induced by 2 h of non-invasive respiratory support help early predict the risk of treatment failure. LUS score improved only in responders and was an independent predictor of failure.
参考来源
- Mongodi S, Santangelo E, Grieco DL, et al. Early lung ultrasound score changes predict the failure of non-invasive respiratory supports in acute hypoxemic patients: a multicenter prospective observational study. Crit Care. 2026. PMID: 41501886. doi:10.1186/s13054-025-05791-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。